Pluristem applies for U.S. approval of bone marrow drug

TEL AVIV (Reuters) – Pluristem Therapeutics Inc will apply to the U.S. Food and Drug Administration for approval of its placenta-based stem cell treatment for aplastic bone marrow as an orphan drug or rare disease treatment, it said on Monday. Gaining orphan drug status is part of Pluristem’s strategy for penetrating the bone marrow recovery market, starting with treatment of aplastic anaemia, a disease that affects five to 10 people in every million. …